Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • AstraZeneca wins UK...

    AstraZeneca wins UK cost approval for longer use of heart drug

    Written by savita thakur thakur Published On 2016-08-19T12:45:05+05:30  |  Updated On 19 Aug 2016 12:45 PM IST
    AstraZeneca wins UK cost approval for longer use of heart drug

    Long term use of AstraZeneca's blood thinner Brilinta has been recommended as a cost-effective option for treating patients after a heart attack, Britain's healthcare cost watchdog NICE said.


    Ticagrelor 60 mg sold in Britain as Brilique for just under 1 pound ($1.30) a pill could help "many thousands of people" when given twice a day alongside aspirin, the National Institute for Health and Care Excellence (NICE) said.


    In the United States, the wholesale acquisition cost is $5.14 a pill, although most U.S. patients are eligible for savings programs.


    A higher 90 mg dose of Brilique is already recommended for 12 months after a heart attack. Now new NICE draft guidance supports continued use at a lower dose for a further three years to reduce the risk of fresh heart attacks or strokes.


    The drug is an important driver of future sales for AstraZeneca, which believes it can eventually sell $3.5 billion a year. Global sales in the first half of 2016 were $395 million.


    The low-dose version of the medicine was recommended for long-term use by the U.S. Food and Drug Administration in September 2015 and by European authorities in February 2016.

    approvalAstraZeneca'sblood thinnerheart attackheart drugsNational Institute for Health and Care ExcellenceNICEstrokeUS Food & Drug AdministrationUSFDA
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok